Stock of the Day

August 18, 2022

Atara Biotherapeutics (ATRA)

$8.90
-$0.30 (-3.3%)
Market Cap: $92.35M

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Today's Trend

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is edging higher after a strong multiweek run, but today’s move appears to be driven mainly by a mix of positive clinical/regulatory optimism and headline risk from ongoing securities litigation.

  • Investor sentiment has improved after reports that the FDA outlined a regulatory pathway for Atara’s lead candidate, tab-cel, reviving hopes for potential U.S. approval following two prior complete response letters. Article Title
  • Several law firms issued reminders about a May 22 lead-plaintiff deadline in a securities class action against Atara, keeping attention on the company’s legal overhang and potentially limiting gains. Article Title
  • Atara also disclosed insider sales by its CEO and chief accounting officer, but the company said the transactions were made to cover tax withholding tied to equity vesting, which makes them less concerning than open-market selling. Article Title
  • The newly filed class action and repeated investor-rights solicitations highlight allegations of prior securities-law violations, creating a legal overhang that could weigh on ATRA if investor focus shifts from the FDA path back to litigation risk. Article Title

Overall, Atara Biotherapeutics (ATRA) looks to be getting support from renewed optimism around tab-cel, while the stock’s upside is tempered by ongoing class-action headlines and recent insider-sale disclosures.

← Previous Stock of the DayNext Stock of the Day →

Recent News